RxDoctor Payments Data

Donesha Garrett, PA

Physician Assistant · Okemos, MINPI 1821684804

Payments from drug & device makers

$4,487in general payments, 2019–2025

Across 236 payments — averaging $19.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$581
  • AbbVie$577
  • GSK$498
  • Novo Nordisk$390
  • Supernus Pharmaceuticals, Inc.$369
  • Otsuka America Pharmaceutical, Inc.$214
  • plus $2K from 30 others

What the payments were for

  • Food & beverage$4,487100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,487 in reported general payments places this provider in the 90th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$410
Medicare patients
20
Services billed
37

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide60$59,870
EliquisApixaban65$39,692
JardianceEmpagliflozin47$26,909
OzempicSemaglutide23$20,977
MounjaroTirzepatide21$20,502
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$14,850
FarxigaDapagliflozin Propanediol20$12,533
JanuviaSitagliptin Phosphate16$9,535
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$7,840
MyrbetriqMirabegron11$5,987
Varenicline Tartrate14$3,859
Ventolin HfaAlbuterol Sulfate50$2,949
Albuterol Sulfate HfaAlbuterol Sulfate88$2,935
Arnuity ElliptaFluticasone Furoate12$2,383
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$2,128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Olanzapine$99$80,880146 claims
PfizerEliquis$145$39,69265 claims
Novo NordiskOzempic$390$20,97723 claims
GSKTrelegy Ellipta, Arnuity Ellipta$498$17,23336 claims
AstraZenecaFarxiga$20$12,53320 claims
MerckJanuvia$52$9,53516 claims
Astellas Pharma US IncMyrbetriq$184$5,98711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Okemos

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →